Kyverna Therapeutics Inc.
KYTX | NASDAQ
$7.12
-$0.01 (-0.14%)
At close: Sep 21, 2026, 4:00 PM ET
$7.07
-$0.05 (-0.64%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 |
|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | 7.03M | 5.66M |
Cost of Revenue | n/a | 2.13M | 1.71M | n/a | n/a |
Gross Profit | n/a | -2.13M | -1.71M | 7.03M | 5.66M |
Operating Income | -169.83M | -142.6M | -62.41M | -29.38M | -26.35M |
Interest Income | 9.09M | 15.36M | 2.28M | 565K | 1K |
Pretax Income | -161.31M | -127.48M | -60.37M | -28.89M | -26.35M |
Net Income | -161.31M | -127.48M | -60.37M | -28.89M | -26.35M |
Selling & General & Admin | 36.11M | 30.13M | 12.48M | 8.01M | 6.15M |
Research & Development | 133.72M | 112.47M | 48.22M | 28.4M | 25.85M |
Other Expenses | n/a | -2.13M | n/a | n/a | n/a |
Operating Expenses | 169.83M | 140.47M | 60.7M | 36.41M | 32M |
Interest Expense | 489K | 142K | 187K | 65K | 3K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 169.83M | 142.6M | 62.41M | 36.41M | 32M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 44.26M | 38.33M | 673.62M | 25.8M | 25.8M |
Shares Outstanding (Diluted) | 44.26M | 38.33M | 673.62M | 25.8M | 25.8M |
EPS (Basic) | -3.64 | -3.33 | 0 | -1.12 | -1.02 |
EPS (Diluted) | -3.64 | -3.33 | 0 | -1.12 | -1.02 |
EBITDA | -159.02M | -125.2M | -58.47M | -27.78M | -25.76M |
EBIT | -160.82M | -127.34M | -60.18M | -28.83M | -26.35M |
Depreciation & Amortization | 1.8M | 2.13M | 1.71M | 1.05M | 586K |
Add to Watchlist
Select watchlists to add or remove KYTX